Natriuretic peptide, brain

Base Information

• Chemical Name: Natriuretic peptide, brain
• CAS No.: 114471-18-0
• Deprecated CAS: 132194-29-7
• Molecular Formula: C143H244N50O42S4
• Molecular Weight: 3464.04
• DSSTox Substance ID: DTXSID101026612
• NCI Thesaurus Code: C47636
• ChEMBL ID: CHEMBL1643388
• Mol file: 114471-18-0.mol

Synonyms:B-Type Natriuretic Peptide;BNP 32;BNP Gene Product;BNP-32;Brain Natriuretic Peptide;Brain Natriuretic Peptide 32;Brain Natriuretic Peptide-32;Natrecor;Natriuretic Factor 32;Natriuretic Factor-32;Natriuretic Peptide Type B;Natriuretic Peptide Type-B;Natriuretic Peptide, B-Type;Natriuretic Peptide, Brain;Natriuretic Peptide, Type-B;Natriuretic Peptide-32, Brain;Nesiritide;Peptide, Brain Natriuretic;Peptide-32, Brain Natriuretic;Type B Natriuretic Peptide;Type-B Natriuretic Peptide;Ventricular Natriuretic Peptide, B type;Ventricular Natriuretic Peptide, B-type

Chemical Property of Natriuretic peptide, brain

Chemical Property:

• Appearance/Colour: powder
• Refractive Index: 1.679
• PSA: 1613.94000
• Density: 1.529 g/cm³
• LogP: -1.27910
• Storage Temp.: −20°C
• Solubility.: ≥206.6 mg/mL in DMSO
• XLogP3: -16.7
• Hydrogen Bond Donor Count: 56
• Hydrogen Bond Acceptor Count: 55
• Rotatable Bond Count: 91
• Exact Mass: 3462.7410615
• Heavy Atom Count: 239
• Complexity: 7750

Purity/Quality:

Greater than 95.0% ^*data from raw suppliers

Brain Natriuretic Peptide 32 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C3CCCN3C(=O)C(CO)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC4=CN=CN4)C(=O)O)CC(C)C)CO)CO)CO)CO
• Isomeric SMILES: CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CN=CN4)C(=O)O)CC(C)C)CO)CO)CO)CO
• Biological functions: The biological actions of BNP are overlapped with those of ANP because they share the same functional receptor, NPR-A . Briefly, BNP induces natriuresis and diuresis by increasing the glomerular filtration rate and decreasing water and sodium reabsorption by the kidney. In addition, BNP decreases aldosterone secretion from the adrenal and vasopressin secretion from the posterior pituitary, which also accelerates natriuresis and diuresis. BNP also decreases systemic vascular resistance by its direct vasorelaxant action. Thus, the net effect of BNP is to decrease blood volume (preload) and systemic blood pressure (afterload), thereby protecting cardiac function. In eels, again similarly to ANP actions, BNP decreases water intake, plasma sodium concentration, and aortic pressure, but the effect is weaker than that of ANP and VNP in the case of eels that have VNP.
• Description: B-type natriuretic peptide is the only cardiac natriuretic peptide common to all vertebrate species thus far examined. The plasma BNP level is used as a robust and reliable biomarker for the diagnosis and prognosis of heart failure. BNP was isolated in 1988 from porcine brain extracts and was thus named the brain natriuretic peptide. Soon thereafter, BNP was found to be expressed abundantly in the cardiac ventricle and scarcely in the brains of humans and rats. Currently, BNP has been recognized as a principal cardiac hormone and referred to as the B-type natriuretic peptide.
• Uses: hemostatic, antimicrobial
• Clinical Use: The severity of CHF assessed by the New York Heart Association (NYHA) functional classification is correlated positively with the elevation of plasma BNP and NT-proBNP levels. Therefore, these peptides are used for the diagnosis and management of patients with CHF. The use of a recombinant BNP, nesiritide, for treatment has been approved by the US Food and Drug Administration. It has beneficial effects in patients with acute, decompensated heart failure; however, it is reported to increase the risk of renal dysfunction and mortality. Further evaluation is required for the clinical use of nesiritide.